Literature DB >> 36056183

The role of ferroptosis in prostate cancer: a novel therapeutic strategy.

Yue Wang1, Yifan Ma2, Kui Jiang3.   

Abstract

The incidence of prostate cancer is the second most among male cancers after lung cancer. Prostate cancer develops rapidly and is inclined to metastasize, and castration-resistant prostate cancer (CRPC) can be formed in the later stage, which brings great challenges to the prognosis and treatment. At present, the main treatment of prostate cancer is generally divided into four methods: surgery, chemotherapy, radiotherapy and endocrine therapy. However, the efficacy of these methods fails to satisfy the demands of patient prognosis. Ferroptosis is a newly discovered iron-dependent process, characterized by lipid peroxidation. Ferroptosis is associated with many diseases, especially tumor growth. In recent years, inhibiting tumor growth and overcoming tumor drug resistance by inducing ferroptosis has become a hot research topic. Previous studies have shown that induction of ferroptosis may be a new treatment for prostate cancer. We review the research progress of ferroptosis in prostate cancer in order to provide highly effective therapies for patients with prostate cancer.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36056183     DOI: 10.1038/s41391-022-00583-w

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.455


  61 in total

1.  Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines.

Authors:  A S Cheung; D Pattison; I Bretherton; R Hoermann; D Lim Joon; E Ho; T Jenkins; E J Hamilton; K Bate; I Chan; J D Zajac; M Grossmann
Journal:  Andrology       Date:  2013-05-20       Impact factor: 3.842

Review 2.  Diagnostic and Therapeutic Strategies for Prostate Cancer.

Authors:  Mary Nguyen-Nielsen; Michael Borre
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

3.  Membrane Damage during Ferroptosis Is Caused by Oxidation of Phospholipids Catalyzed by the Oxidoreductases POR and CYB5R1.

Authors:  Bo Yan; Youwei Ai; Qi Sun; Yan Ma; Yang Cao; Jiawen Wang; Zhiyuan Zhang; Xiaodong Wang
Journal:  Mol Cell       Date:  2020-12-14       Impact factor: 17.970

4.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

5.  Ferroptosis: an iron-dependent form of nonapoptotic cell death.

Authors:  Scott J Dixon; Kathryn M Lemberg; Michael R Lamprecht; Rachid Skouta; Eleina M Zaitsev; Caroline E Gleason; Darpan N Patel; Andras J Bauer; Alexandra M Cantley; Wan Seok Yang; Barclay Morrison; Brent R Stockwell
Journal:  Cell       Date:  2012-05-25       Impact factor: 41.582

6.  Effects of Breast and Prostate Cancer Metastases on Lumbar Spine Biomechanics: Rapid In Silico Evaluation.

Authors:  J Lorkowski; O Grzegorowska; M S Kozień; I Kotela
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

Review 7.  Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies.

Authors:  Heide Schatten
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

8.  Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.

Authors:  Karen E Hoffman; David F Penson; Zhiguo Zhao; Li-Ching Huang; Ralph Conwill; Aaron A Laviana; Daniel D Joyce; Amy N Luckenbaugh; Michael Goodman; Ann S Hamilton; Xiao-Cheng Wu; Lisa E Paddock; Antoinette Stroup; Matthew R Cooperberg; Mia Hashibe; Brock B O'Neil; Sherrie H Kaplan; Sheldon Greenfield; Tatsuki Koyama; Daniel A Barocas
Journal:  JAMA       Date:  2020-01-14       Impact factor: 56.272

9.  Management of biochemical recurrence after primary localized therapy for prostate cancer.

Authors:  Oussama M Darwish; Ganesh V Raj
Journal:  Front Oncol       Date:  2012-05-23       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.